Traders bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Friday. $269.87 million flowed into the stock on the tick-up and $106.26 million flowed out of the stock on the tick-down, for a money net flow of $163.61 million into the stock. Of all equities tracked, Pfizer had the 8th highest net in-flow for the day. Pfizer traded down ($0.15) for the day and closed at $36.77

A number of analysts have recently weighed in on PFE shares. Piper Jaffray Cos. reissued an “overweight” rating and issued a $54.00 price objective on shares of Pfizer in a research report on Sunday, March 20th. S&P Equity Research reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, April 12th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $36.00 price target on shares of Pfizer in a research report on Tuesday, April 5th. Bank of America Corp. reaffirmed a “buy” rating and set a $28.25 price target (down previously from $38.48) on shares of Pfizer in a research report on Tuesday, May 10th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, May 6th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $38.11.

The firm has a 50-day moving average of $35.15 and a 200 day moving average of $32.24. The company has a market cap of $223.00 billion and a price-to-earnings ratio of 30.14.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.12. The firm earned $13 billion during the quarter, compared to analyst estimates of $12 billion. Pfizer’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.51 EPS. On average, equities analysts predict that Pfizer Inc. will post $2.44 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be given a $0.30 dividend. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.26%.

In related news, EVP Laurie J. Olson sold 4,700 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $33.50, for a total value of $157,450.00. Following the completion of the sale, the executive vice president now owns 71,659 shares in the company, valued at $2,400,576.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Frank A. Damelio sold 100,000 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the completion of the sale, the executive vice president now owns 472,994 shares of the company’s stock, valued at approximately $16,313,563.06. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its stake in shares of Pfizer by 16.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,378,870 shares of the biopharmaceutical company’s stock worth $786,951,000 after buying an additional 3,522,873 shares during the last quarter. Longview Partners Guernsey LTD boosted its position in shares of Pfizer by 1.1% in the fourth quarter. Longview Partners Guernsey LTD now owns 20,115,395 shares of the biopharmaceutical company’s stock worth $649,325,000 after buying an additional 220,284 shares during the period. Swiss National Bank boosted its position in shares of Pfizer by 1.4% in the fourth quarter. Swiss National Bank now owns 12,075,889 shares of the biopharmaceutical company’s stock worth $389,810,000 after buying an additional 161,900 shares during the period. Jennison Associates LLC boosted its position in shares of Pfizer by 24.7% in the fourth quarter. Jennison Associates LLC now owns 11,912,098 shares of the biopharmaceutical company’s stock worth $384,523,000 after buying an additional 2,361,977 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Pfizer by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 11,774,052 shares of the biopharmaceutical company’s stock worth $380,066,000 after buying an additional 186,091 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.